UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
September
2, 2008
Date
of
Report (Date of earliest event reported)
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
|
State
of New York
|
1-10113
|
11-0853640
|
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
|
of
Incorporation)
|
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR
240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17CFR240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e- 4(c))
Item
8.01 Other
Events.
On
September 2, 2008 we announced that
Andy
Reddick has resumed full responsibilities as President and Chief Executive
Officer following a medical leave of absence initiated in February of this
year.
We expect Mr. Reddick’s travel schedule will be limited for the foreseeable
future.
A press
release announcing the foregoing is being furnished as Exhibit
99.1.
Item
9.01 Financial
Statements and Exhibits.
|
Exhibit
|
||
|
Number
|
Description
|
|
|
99.1
|
Press
Release dated September 2, 2008 Announcing Resumption of Full
Responsibilities of Registrant’s Chief Executive
Officer.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
ACURA
PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/
Peter A. Clemens
|
|
Peter
A. Clemens
|
|
|
Senior
Vice President & Chief Financial
Officer
|
|
Date: September
2, 2008
EXHIBIT
INDEX
|
Description
|
||
|
99.1
|
Press
Release dated September 2, 2008 Announcing Resumption of Full
Responsibilities of Registrant’s Chief Executive
Officer.
|
 |
Acura
Pharmaceuticals Contact:
|
|
Peter
A. Clemens, SVP Investor Relations & CFO
|
|
ACURA
PHARMACEUTICALS, INC. ANNOUNCES RETURN OF
PRESIDENT
AND CEO FROM MEDICAL LEAVE
Palatine,
IL, September 2, 2008:
Acura
Pharmaceuticals, Inc. (NASDAQ: ACUR) announced today that Andy Reddick has
resumed full responsibilities as President and Chief Executive Officer following
a medical leave of absence initiated in February of this year. The Company
expects Mr. Reddick’s travel schedule will be limited for the foreseeable
future.
About
Acura Pharmaceuticals, Inc.
Acura
Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research,
development and manufacture of innovative Aversion® (abuse deterrent) Technology
and related product candidates. For more information, please visit
www.acurapharm.com.